Receptor tyrosine kinase (RTK) genomic alterations including ERBB2 (n=13), EGFR (n=5), FGFR2 (n=3) and KDR (n=4) were detected in 20.5% of GC cases (n=22). This evidence concerns the gene EGFR and gastric cancer.